I hesitate to post this as some of you will strongly disagree with my thoughts, but for full disclosure, this was my email to Stephanie, which she said she would send to the BOD
Hi Stephanie,
I thought the earnings call was very odd....completely scripted and only one analyst on the call. Are Roth and Noble still following PPHM? If not, do you know why not? It seems to many of us IHUB PPHM board members that there was an even greater than normal failure of management to capitalize on the good news presented on Avid's performance. We had hoped that this quarter's results would provide the opportunity to finally get the stock price better aligned with the perceived value of Avid and the body of research and patents PPHM has. Obviously, as always, that did not happen. We are at 52 week lows AGAIN. King professes to WANT to get the stock price aligned with value, but they never seem to do more than make verbal assertions that it is worth more, blah blah. Obviously, Wall Street has no faith in the guys steering this ship.
I see the poster from the Vienna presentation is not on the website. Is it possible to see a copy of it somewhere? Many investors would like to see that particular presentation.
I would like the following suggestions be submitted to the Board of Directors:
1. Hire a respected, qualified Treasurer with Biotech experience to assume responsibility for all financing and ATM sales with Lytle either leaving or moved to a lesser position since he seems completely unable to run the financial side of the business with any skill or financial prudence. He constantly uses the ATM to suppress any increase in the pps at the same time continuing to dilute the existing shareholders gives the appearance that he is not acting in the shareholders interest and may be facilitating the lowest possible option award price for benefit of management and the board of directors individually.
2. The board of directors should defer all payments and option awards to themselves until the stock price has recovered to at least $2 per share and compliance is regained with our NASDAQ listing. Senior management should defer all bonuses and option awards until NASDAQ compliance is regained. The BOD and senior management need to have their interests aligned with the shareholder interests instead of only the shareholders suffering from the pathetic stock price.
3. Every effort should be made to avoid the reverse split. Management always gives the impression that "it's certainly not my fault the share price isn't properly valued by the market". That is simply wrong. It IS their fault. They are unable to make their case to the market that PPHM has a high intrinsic value, far above the current price. King simply stating that the market doesn't recognize the value means nothing. Just empty words. If King is unable to perform his duties as CEO, duties which include convincing the market that PPHM has much higher value than is currently attributed to it, then he should resign or become Chief Scientific Officer and someone who has the ability to deal with Wall Street with credibility and trust.
4. Bring on at least one additional independent member to the Board of Directors who has biotech experience and is unrelated in any way to the current group. The existing board is seen for what they are, an interrelated group with no relevant experience incapable of advancing this company in a positive direction.
Thank you for your assistance in getting this message to the Board.
Gwen
